TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28463149
Drug: Short-term ADT
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month)
Study: 23540577
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program
Study: 8797346
Drug: Gd-BOPTA (E7155)
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gd-BOPTA (E7155) low dose (0.025 mmol/kg)
Study: 8797346
Drug: Gd-BOPTA (E7155)
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gd-BOPTA (E7155) medium dose (0.05 mmol/kg)
Study: 8797346
Drug: Gd-BOPTA (E7155)
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gd-BOPTA (E7155) high dose (0.1 mmol/kg)
Study: 1514709
Drug: Iomeprol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol, 150 mg iodine/mL
Study: 1514709
Drug: Iopamidol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol, 150 mg iodine/mL
Study: 31968102
Drug: HDL-C raising
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL-C raising genetic variants in the gene locus of CETP inhibitors
Study: 31582195
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy for Cognitively Impaired
Study: 26963909
Drug: OEPA chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OEPA chemotherapy
Study: 20075695
Drug: Fiber supplementation
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplementation for fecal incontinence (FI), specific dosage and duration not mentioned.
Study: 17327409
Drug: Eltrombopag (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (5, 10, 25, 30, 50, and 75 mg)
Study: 16263675
Drug: Special Operations
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Special Operations Forces Tactical Tourniquet (Tactical Medical Solutions, LLC)
Study: 8672759
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg daily for 3 weeks, 15 mg for 1 week, and no prednisolone for 2 weeks prior to lymphoblastoid IFN therapy (Group 1)
Study: 8672759
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily for 2 weeks, 30 mg for 2 weeks, 20 mg for 2 weeks, and no prednisolone for 2 weeks prior to INF alpha‐2a therapy (Group 2)
Study: 8672759
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of prednisolone (40 mg)
Study: 6402387
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol (EE) administered orally at 36 hours after LH peak and again at 48 hours
Study: 6402387
Drug: Endometrial biopsies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsies from treatment cycle
Study: 26773183
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (QT) for 10 days
Study: 26773183
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (ST) for 10 days
Study: 26773183
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (CT) for 10 days
Study: 18614781
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (367 patients)
Study: 15642905
Drug: MRI scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI scans before antiepileptic medication and follow-up MRI scans after 1, 2 to 3, and 5 years of treatment
Study: 12145071
Drug: Forearm IVRA
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm IVRA with 100 mg lidocaine and 10 mg ketorolac
Study: 12145071
Drug: Upper Arm
Normalized name: A And D Medical UA-651 Upper Arm BPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper Arm IVRA with 200 mg lidocaine and 20 mg ketorolac
Study: 7733838
Drug: Levorotatory form
Normalized name: methyldopa (levorotatory)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levorotatory form of hydroxytryptophan (1000 mg/d)
Study: 22495787
Drug: UC781 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC781 vaginal gel
Study: 19369187
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (Control group, n = 46)
Study: 15024596
Drug: Double Stapled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Stapled Trans‐Anal Rectal Resection (STARR Group)
Study: 11597813
Drug: Accelerated Hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Hyperfractionated (AH) whole‐brain radiation therapy (1.6 Gy b.i.d. to 54.4 Gy)
Study: 11597813
Drug: Accelerated Fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Fractionation (AF) whole‐brain radiation therapy (3 Gy q.d. to 30 Gy)
Study: 9688452
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g daily + amikacin (reference regimen)
Study: 8082347
Drug: Bolus rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus rt-PA (0.6 mg/kg/15 min, maximum of 50 mg)
Study: 8082347
Drug: 2-h rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-h rt-PA (100 mg over 2 h)
Study: 1091965
Drug: Buffered acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered acetylsalicylic acid (ASA) preparation
Study: 1091965
Drug: Plain acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain acetylsalicylic acid (ASA) tablets
Study: 30159738
Drug: Monovisc™ (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovisc™ (4 ml single injection)
Study: 30159738
Drug: Saline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (4 ml injection of 0.9% saline)
Study: 25269659
Drug: Pump 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump 2 (Asante Snap Insulin Pump)
Study: 22834767
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily for 6 weeks
Study: 21270359
Drug: 15 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg/d cholecalciferol (D3) supplementation
Study: 21270359
Drug: 5 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/d cholecalciferol (D3)
Study: 21270359
Drug: 10 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/d cholecalciferol (D3)
Study: 17137511
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous adenosine
Study: 12672714
Drug: Baseline (BL)
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (BL) diet (35% fat, 14% SFA, 13% MUFA, 8% PUFA, 147 mg cholesterol/1000 kcal)
Study: 12672714
Drug: Reduced-fat (RF)
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-fat (RF) diet (26% fat, 4% SFA, 11% MUFA, 11% PUFA, 45 mg cholesterol/1000 kcal)
Study: 12672714
Drug: Low-fat (LF)
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat (LF) diet (15% fat, 5% SFA, 5% MUFA, 3% PUFA, 35 mg cholesterol/1000 kcal)
Study: 1418778
Drug: Zidovudine +
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine + Acyclovir (800 mg every 6 h)
Study: 6396834
Drug: Single-dose trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose trimethoprim-sulfamethoxazole (4 tablets)
Study: 6396834
Drug: 3-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Study: 6396834
Drug: 10-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Study: 26466321
Drug: Bioimpedance intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioimpedance intervention group with increased dialysate glucose prescription
Study: 9501747
Drug: Paroxetine (33.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (33.9 mg daily)
Study: 9501747
Drug: Imipramine (162.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (162.5 mg daily)
Study: 7663312
Drug: ritanserin 5
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin 5 mg/day
Study: 7663312
Drug: ritanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin 10 mg/day
Study: 630965
Drug: Methylprednisolone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (two large doses administered intravenously)
Study: 30739259
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (PAC) > 3 cycles
Study: 30739259
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (PAC) 1-3 cycles
Study: 27655012
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion (0.5 μg/kg per min for 4 h)
Study: 16669955
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg alicaforsen
Study: 16669955
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg alicaforsen
Study: 12783912
Drug: Rofecoxib, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 25 mg once daily
Study: 12783912
Drug: Naproxen, 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 220 mg twice daily
Study: 8931866
Drug: PAMBA 100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAMBA 100-200 mg daily for 7 to 26 days with moderate corticosteroids (mean dose 36.1 mg prednisolone equivalent)
Study: 8931866
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids (mean 94.2 mg prednisolone equivalent) and immunosuppressive drugs
Study: 2996580
Drug: Nedocromil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (2 mg) by inhalation
Study: 31021023
Drug: CSF IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF IL-6 concentration >50 pg/ml in neurosarcoidosis patients
Study: 31021023
Drug: Anti-IL-6 monoclonal
Normalized name: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-6 monoclonal antibody treatment in a refractory neurosarcoidosis patient
Study: 25972024
Drug: Sustained eradication
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained eradication of Pseudomonas aeruginosa (Pa) after early antipseudomonal therapy
Study: 25972024
Drug: Nonsustained eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsustained eradication of Pseudomonas aeruginosa (Pa) after early antipseudomonal therapy
Study: 18541884
Drug: NGX‐4010 (high-concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX‐4010 (high-concentration capsaicin patch)
Study: 18541884
Drug: Control (low-concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low-concentration capsaicin patch)
Study: 16028530
Drug: Recombinant IFN‐alpha2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IFN‐alpha2 with complex immunoglobulin preparation (CIP) via rectal method
Study: 16028530
Drug: Recombinant IFN‐alpha2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IFN‐alpha2 with complex immunoglobulin preparation (CIP) via inhalation method
Study: 12759839
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated PMMA intraocular lenses
Study: 10078608
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) at low concentration (0.1 microg ml(‐1))
Study: 7672149
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection with vigorous aspiration of oocyte cytoplasm
Study: 28841431
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (target SBP: 120 mmHg)
Study: 28841431
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (target SBP: 140 mmHg)
Study: 24130735
Drug: Non-hypnotic imaginative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypnotic imaginative suggestion
Study: 18923231
Drug: Celacade therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celacade therapy
Study: 11925376
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (multiple low-dose 0.25 mg and single high-dose 3 mg)
Study: 11925376
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist and GnRH agonist (long protocol)
Study: 9593172
Drug: WR 238605,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 238605, a single oral dose of 600 mg administered 1 day prior to challenge
Study: 8169182
Drug: Clonazepam (CZP)
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam (CZP) up to 2 mg/day for 4 weeks
Study: 3198992
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg IV as bolus)
Study: 20152561
Drug: Clopidogrel tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel tapering regimen for 4 weeks
Study: 20152561
Drug: Continued daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued daily clopidogrel intake for 4 more weeks
Study: 18953552
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B nasal spray (5 mg/ml)
Study: 18953552
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (lacking amphotericin B)
Study: 12186600
Drug: Ginkgo, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo, 40 mg 3 times per day (n = 115)
Study: 897855
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg injected intramuscularly half an hour before the meal
Study: 897855
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg injected intramuscularly half an hour before the meal
Study: 31337342
Drug: Gemcitabine 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 900 mg/m2 on Days 1 and 8, and docetaxel 70 mg/m2 on Day 8 in 3-week cycles until disease progression or treatment failure.
Study: 28168925
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull energy drink 250 mL
Study: 28168925
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull Sugarfree energy drink 250 mL
Study: 28168925
Drug: Placebo 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 250 mL
Study: 25639864
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) (C arm)
Study: 12694429
Drug: NK 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK 10% gel
Study: 12694429
Drug: NK 5%
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NK 5% gel
Study: 1643700
Drug: Intravenous idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous idarubicin (12 mg/m2)
Study: 1643700
Drug: Oral idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral idarubicin (30-35 mg/m2)
Study: 6433636
Drug: Aspirin (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (median dose 31 mg/kg/day)
Study: 27441478
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose melatonin treatment group (10mg capsule once daily)
Study: 27441478
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose melatonin treatment group (20mg capsule once daily)
Study: 16214452
Drug: Highest quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quintile of magnesium intake (median 433 mg/day)
Study: 9734735
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of octreotide
Study: 8295285
Drug: Captopril, 50
Normalized name: Captopril, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 50 mg, twice per day
Study: 2738792
Drug: Elimination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elimination diet with double-blind, placebo-controlled oral food challenges
Study: 1092728
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin daily
Study: 31274533
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention of PrEP initiation and retention
Study: 28689520
Drug: Terlipressin 12-hour
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 12-hour therapy (Group-B)
Study: 28689520
Drug: Terlipressin 72-hour
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 72-hour therapy (Group-A)
Study: 17563155
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for anxiety disorders (AD)
Study: 9625683
Drug: Ursodiol, 300
Normalized name: Ursodiol, 300 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg)
Study: 1734400
Drug: L-epinephrine
Normalized name: dl-Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-epinephrine
Study: 7839475
Drug: Dexamethasone (greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (greater than 0.6 mg/kg)
Study: 7839475
Drug: Steroids (when
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (when intubation is necessary)
Study: 3203714
Drug: Emthexat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emthexat 2.5 mg tablets
Study: 3203714
Drug: Methotrexate 2.5
Normalized name: methotrexate 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 2.5 mg tablets
Study: 2197851
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g protein with 50 g glucose
Study: 2197851
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g protein with 50 g glucose
Study: 2197851
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g protein with 50 g glucose
Study: 2197851
Drug: Various amounts
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various amounts of protein with 50 g glucose
Study: 30673020
Drug: Diuretics (chlorthalidone/amiloride)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (chlorthalidone/amiloride)
Study: 28431534
Drug: Spirulina platensis
Normalized name: SPIRULINA PLATENSIS
DrugBank: Spirulina platensis (DB14744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina platensis (500 mg, twice daily)
Study: 28431534
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch pills, two daily)
Study: 24940324
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac sodium 75mg
Study: 21701422
Drug: Systemic EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Systemic EGF treatment initiated immediately after pneumonia onset
Study: 21701422
Drug: Systemic EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Systemic EGF treatment initiated 24 hours after pneumonia onset
Study: 17200252
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion (0.5 U/kg per hour)
Study: 9932161
Drug: MTHF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as i.v. bolus injection
Study: 9932161
Drug: MTHF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as a two-hour infusion
Study: 29889748
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol and 100 mg progesterone
Study: 29889748
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg estradiol and 100 mg progesterone
Study: 29889748
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg estradiol and 50 mg progesterone
Study: 29889748
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg estradiol and 50 mg progesterone
Study: 26983396
Drug: LM +
Normalized name: SlowMag Calm + Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM + 30 g/day brown milled flaxseed for 12 weeks
Study: 24731416
Drug: UPPP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPPP with oral appliance (UA group)
Study: 22614152
Drug: Enalapril (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.1 to 0.30 mg/kg/day)
Study: 20375709
Drug: H5N1 vaccine
Normalized name: Influenza H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 vaccine (1.9 microg HA/AS03(B), 3.75 microg HA/AS03(B), and 3.75 microg HA/AS03(A))
Study: 20375709
Drug: H5N1 vaccine
Normalized name: Influenza H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 vaccine